OxervateUSPackag_1534470705843-3-HR The safety and efficacy of Oxervate was evaluated in 2 independent, double-masked, randomized, multicenter, controlled clinical trials involving patients with ...

Please provide your email address to receive an email when new articles are posted on . There is more than one way to treat neurotrophic keratopathy. In a debate on the topic, Fasika Woreta, MD, MPH, ...

Please provide your email address to receive an email when new articles are posted on . Stonecipher, a cornea specialist at the University of North Carolina and Tulane, called Oxervate ...

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic ...

Patients in the UK will get early access to Dompé farmaceutici's neurotrophic keratitis drug Oxervate (cenegermin), the Medicines and Healthcare products Regulatory Agency (MHRA) announced Wednesday.

European regulators have agreed to review Italian drugmaker Dompe's orphan drug Oxervate, opening the door to what may potentially become the first biotech treatment available to patients with the ...

The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that ...

Dompé, a biopharmaceutical company, announced that the Committee for Human Medicinal Products (CHMP) of European Medicines Agency (EMA) has released a positive opinion, recommending the marketing ...

The origin of neurotrophic keratitis is related to a trigeminal nerve impairment (one of the nerves responsible for the eye anatomy and function), which can lead to the loss of corneal sensitivity. In ...

MILAN and SAN BRUNO, Calif., March 12, 2019 /PRNewswire/ -- Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé), announced today that the National Organization for Rare Disorders (NORD) ...

In 2015, the product was designated as an orphan drug in Europe for the treatment of neurotrophic keratitis, a rare eye disease that affects less than 5 out of every 10,000 people [1]. Until now, ...